Antibodies that bind human c6 and uses thereof
AssigneeRegenesance B.V.
InventorsFrank BAAS, Marc A. VAN DIJK
Life of this patent
Estimating the term…
Abstract
Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
Claims26
A method of inhibiting Membrane Attack Complex (MAC) formation or activity in a subject, the method comprising administering to the subject an antibody in an amount effective to inhibit MAC formation or activity in the subject, wherein the antibody binds to human C6 and exhibits at least three of the following properties:
- (a) has an IC50 in a haemolytic assay of 0.5 μg/ml or less;
- (b) has a KD, as determined by surface plasmon resonance, of 1×10−8 M or less;
- (c) has an antibody-C6 binding half-life, as determined by surface plasmon resonance, of 40 hours or greater;
- and
- (d) cross-reacts with cynomolgus monkey C6.
A method of treating, preventing or reducing symptoms of a disorder mediated by undesired activity of the complement system in a subject, the method comprising administering to the subject an effective amount of an antibody, wherein the antibody binds to human C6 and exhibits at least three of the following properties:
- (a) has an IC50 in a haemolytic assay of 0.5 μg/ml or less;
- (b) has a KD, as determined by surface plasmon resonance, of 1×10−8 M or less;
- (c) has an antibody-C6 binding half-life, as determined by surface plasmon resonance, of 40 hours or greater;
- and
- (d) cross-reacts with cynomolgus monkey C6.
A method of stimulating the regeneration of nerves, or promoting recovery of damaged or degenerated nerves, or reducing or delaying degeneration of nerves in a subject, comprising administering to the subject a therapeutically effective amount of an antibody, wherein the antibody binds to human C6 and exhibits at least three of the following properties:
- (a) has an IC50 in a haemolytic assay of 0.5 μg/ml or less;
- (b) has a KD, as determined by surface plasmon resonance, of 1×10−8 M or less;
- (c) has an antibody-C6 binding half-life, as determined by surface plasmon resonance, of 40 hours or greater;
- and
- (d) cross-reacts with cynomolgus monkey C6.
-5. (canceled)
An expression vector comprising a nucleotide sequence encoding the variable region of a light chain, heavy chain, or both light and heavy chains of an antibody which binds human C6, wherein the antibody comprises heavy chain CDR1, 2 and 3 sequences shown in SEQ ID NOs:
- 6, 7 and 8, respectively, and comprises light chain CDR1, 2 and 3 sequences shown in SEQ ID NOs:
- 11, 12 and 13, respectively.
Dependencies are inferred from the claim text.